Key facts
- Cyclarity Therapeutics’s last known valuation is $34.3M (Dec 2024).
- It has raised $34.0M across 1 recorded rounds; the latest was Early Stage VC ($10.3M) in Dec 2024.
- Notable investors include National Institutes of Health, Formic Ventures, Starbloom Capital, Ki Tua Fund, California Life Sciences — 12 tracked in total.
- Cyclarity Therapeutics has filed 1 Form D with the SEC, most recently Dec 2024 ($10.3M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Cyclarity Therapeutics
Funding rounds
1 roundsAbout Cyclarity Therapeutics
Developer of compound-based drugs designed to treat the underlying causes of age-related diseases. The company's drugs offer simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules to remove arterial plaque by clearing the non-degradable cholesterol, enabling clinicians to provide patients with disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.
- Sector
- Healthcare
- HQ
- Novato, CA, United States
- Founded
- 2019
- Employees
- 11
- Website
- cyclaritytx.com/
- Ownership
- Privately Held (backing)
Cyclarity Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyclarity Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyclarity Therapeutics in its N-PORT filings yet. We sweep new filings monthly.